ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: PAs Available.

January 28, 2005

NIH Revises K Series Awards; RFP Available; Program Announcement

June 9, 1995

New Drug Reverses Damage To Liver In Stem Cell Transplant

September 27, 2002

Immunotherapy Demonstrates Disease Control in Phase II Study

September 28, 2012

FDA Names Director Of New Center For Tobacco Products

September 11, 2009

Foreign awards Less Than 1% Of NCI Budget

June 22, 1990